Shares of medical equipment makers fell Friday on more weak sales reports as hospitals continue to tighten capital spending while the economic outlook remains dim. Mountain View, Calif.-based Hansen Medical (HNSN) said late Thursday it expects fourth-quarter sales between $7.1 million and $7.4 million, far below Wall Street expectations of $12.2 million.
The company, which sells medical robotic technology used with catheters, cited the economy's effect on customer spending.
Shares fell to $5.60 early in the trading session, marking their lowest point in more than two years.
The announcement follows Sunnyvale, Calif.-based Intuitive Surgical's (ISRG) Wednesday announcement that fourth-quarter sales rose 22%. The figure also fell short of Wall Street expectations, with the maker of surgical devices citing weak hospital spending. The stock fell $8.79, or 8%, to $101.75 Friday.Needham & Co. analyst Sameer Harish, meanwhile, downgraded shares of Sunnyvale, Calif.-based Cepheid (CPHD) to "Hold" from "Buy," citing a slowdown in sales of the company's genetic testing systems. "Due to the credit crisis, we believe hospitals may have pushed out GeneXpert and GeneXpert Infinity orders, which were expected to be shipped in the December quarter," he said, in a note to investors. Cepheid shares fell 64 cents, or 6.6%, to $9.04. Meanwhile, Needham colleague Ed Shenkan downgraded shares of Bedford, Mass.-based Hologic (HOLX), which makes digital mammography systems, to "Hold" from "Buy," because of similar concerns. The stock fell 68 cents, or 6%, to $10.75 in afternoon trading, but earlier reached a more than three-year low of $10.34. Elsewhere, shares of Palo Alto, Calif.-based Varian Medical Systems (VAR), which makes radiation therapy systems, fell 3 cents to $32.38.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV